9902644-5
IPOS COPY

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 403/06, 405/04, A61K 31/505, C07D 401/14 // (C07D 403/06, 239:00, 233:00)

A1

(11) International Publication Number: WO 98/49157

(43) International Publication Date: 5 November 1998 (05.11.98)

(21) International Application Number: PCT/EP98/02357

(22) International Filing Date: 17 April 1998 (17.04.98)

(30) Priority Data:
97201259.5 25 April 1997 (25.04.97) EP
(34) Countries for which the regional or international application was filed: DE et al.

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B–2340 Beerse (BE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: ANGIBAUD, Patrick, René [FR/FR]; Janssen–Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F–92787 Issy–les–Moulineaux Cedex 9 (FR). VENET, Marc, Gaston [FR/FR]; Janssen–Gilag S.A., 1, rue Camille Desmoulins, TSA 91003, F–92787 Issy–les–Moulineaux Cedex 9 (FR). FREYNE, Eddy, Jean, Edgard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE).

(74) Agent: QUAGHEBEUR, Luc; Janssen Pharmaceutica N.V., Patent Dept., Turnhoutseweg 30, B–2340 Beerse (BE).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: FARNESYLTRANSFERASE INHIBITING QUINAZOLINONES

(57) Abstract

This invention concerns compounds of formula (I), the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; R^1 and R^2 each independently are hydrogen, hydroxy, halo, cyano, C_{1-6}alkyl, trihalomethyl, trihalomethoxy, C_{2-6}alkenyl, C_{1-6}alkyloxy, hydroxyC_{1-6}alkyloxy, C_{1-6}alkyloxyC_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, aminoC_{1-6}alkyloxy, mono– or di(C_{1-6}alkyl)aminoC_{1-6}alkyloxy, Ar^1, Ar^1C_{1-6}alkyl, Ar^1oxy, Ar^1C_{1-6}alkyloxy; or when on adjacent positions R^1 and R^2 taken together may form a bivalent radical; R^3 and R^4 each independently are hydrogen, halo, cyano, C_{1-6}alkyl, C_{1-6}alkyloxy, Ar^1oxy, C_{1-6}alkylthio, di(C_{1-6}alkyl)amino, trihalomethyl, trihalomethoxy; R^5 is hydrogen, halo, cyano, optionally substituted C_{1-6}alkyl, C_{1-6}alkyloxycarbonyl or Ar^1; or a radical of the formula $-OR^{10}$, $-SR^{10}$, $-NR^{11}R^{12}$; R^6 is an optionally substituted imidazolyl moiety; R^7 is hydrogen or C_{1-6}alkyl provided that the dotted line does not represent a bond; R^8 is hydrogen, C_{1-6}alkyl or Ar^2CH_2 or Het^1CH_2; R^9 is hydrogen, C_{1-6}alkyl, C_{1-6}alkyloxy or halo, or R^8 and R^9 taken together may form a bivalent radical; Ar^1 and Ar^2 are optionally substituted phenyl and Het^1 is optionally substituted pyridinyl; having farnesyltransferase inhibiting activity; their preparation, compositions containing them and their use as a medicine.



(I)